Previous 10 | Next 10 |
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results ...
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will participate in the Oppenheimer 34 th Annual...
2024-01-04 16:17:52 ET More on Lumos Pharma Lumos stock rockets nearly 100% in after-hours trading on study updates Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lumos Pharma For further details see: Lumos Pharma promote...
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit “Duke” Pitukcheewanont, MD, known also as Dr. Duke, to the position of Chief Medical Officer (C...
AUSTIN, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to disc...
AUSTIN, Texas, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the Company will participate in the Piper Sandler 35 th Annual Healthcare Conference being held Nov...
2023-11-08 10:00:55 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector as earnings close in For further details see: Durect, Lumos Pharma among healthcare movers
Lumos Pharma Inc. (LUMO) is expected to report $-1.1 for Q3 2023
2023-11-07 17:22:37 ET More on Lumos Pharma Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript Lumos stock rockets nearly 100% in after-hours trading on study updates Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lum...
2023-11-07 16:47:23 ET More on Lumos Pharma Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lumos Pharma Financial information for Lumos Pharma For further det...
News, Short Squeeze, Breakout and More Instantly...
Lumos Pharma Inc. Company Name:
LUMO Stock Symbol:
NASDAQ Market:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase ...